Formulation and Specifications: Tablets, 40 mg
Indications: Treatment of adult patients with locally advanced or metastatic NSCLC who have experienced disease progression on or after prior treatment with EGFR-TKI and whose presence of a positive EGFR-T790M mutation has been confirmed by testing.
Key points for rational drug use:
1. EGFR-T790M mutation must be clearly detected by an assay approved by the State Drug Administration before dosing.
2. The recommended dose is 80 mg orally once daily on an empty stomach.
3. Common adverse reactions to vomitinib are elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), and prolonged QTc interval on ECG. Be alert for the development of interstitial pneumonia.
4. Avoid combination with strong inducers or strong inhibitors of CYP3A4.